These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27198655)

  • 1. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.
    Yoon HH; Lewis MA; Foster NR; Sukov WR; Khan M; Sattler CA; Wiktor AE; Wu TT; Jenkins RB; Sinicrope FA
    Int J Cancer; 2016 Oct; 139(7):1626-31. PubMed ID: 27198655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
    Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
    BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
    Maron SB; Catenacci DVT
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
    Yoon HH; Shi Q; Sukov WR; Wiktor AE; Khan M; Sattler CA; Grothey A; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
    Clin Cancer Res; 2012 Jan; 18(2):546-54. PubMed ID: 22252257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
    Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
    J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
    Cinar P; Calkins SM; Venook AP; Kelley RK
    Anticancer Res; 2014 Dec; 34(12):7357-60. PubMed ID: 25503172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
    Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
    J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.
    Yoon HH; Sukov WR; Shi Q; Sattler CA; Wiktor AE; Diasio RB; Wu TT; Jenkins RB; Sinicrope FA
    Cancer; 2014 Feb; 120(3):415-24. PubMed ID: 24151090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.
    Madani SH; Rahmati A; Sadeghi E; Khazaei S; Sadeghi M; Payandeh M; Amirifard N
    Asian Pac J Cancer Prev; 2015; 16(17):7755-8. PubMed ID: 26625793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.
    Jin Z; Holubek M; Sukov WR; Sattler CA; Wiktor AE; Jenkins RB; Wu TT; Yoon HH
    Am J Clin Oncol; 2019 Feb; 42(2):190-195. PubMed ID: 30516569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
    Gordon MA; Gundacker HM; Benedetti J; Macdonald JS; Baranda JC; Levin WJ; Blanke CD; Elatre W; Weng P; Zhou JY; Lenz HJ; Press MF
    Ann Oncol; 2013 Jul; 24(7):1754-1761. PubMed ID: 23524864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.
    Koopman T; Smits MM; Louwen M; Hage M; Boot H; Imholz AL
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1343-51. PubMed ID: 25544671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
    Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
    Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
    Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
    Kumarasinghe MP; de Boer WB; Khor TS; Ooi EM; Jene N; Jayasinghe S; Fox SB
    Pathology; 2014 Apr; 46(3):184-7. PubMed ID: 24614718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Targeted Therapies for Esophagogastric Cancer.
    Maron SB; Catenacci DV
    Surg Oncol Clin N Am; 2017 Apr; 26(2):293-312. PubMed ID: 28279470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
    Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
    Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.